Abstract
Obsessive Compulsive Disorder (OCD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Obsessive Compulsive Disorder (OCD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Obsessive-Compulsive Disorder (OCD) Therapeutics market. The report identifies the key trends shaping and driving the global Obsessive-Compulsive Disorder (OCD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Obsessive-Compulsive Disorder (OCD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Obsessive-Compulsive Disorder (OCD) Therapeutics market. Its scope includes -
• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Obsessive-Compulsive Disorder (OCD) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Obsessive-Compulsive Disorder (OCD) Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Obsessive-Compulsive Disorder (OCD) Therapeutics therapeutics market.
• Analysis of key recent licensing and partnership agreements in Obsessive-Compulsive Disorder (OCD) Therapeutics market
Reasons To Buy
The report will enhance your decision making capability. It will allow you to -
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Obsessive-Compulsive Disorder (OCD) Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Obsessive-Compulsive Disorder (OCD) Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Obsessive-Compulsive Disorder (OCD) Therapeutics market landscape? – Identify, understand and capitalize.
Companies Mentioned
Transcept Pharmaceuticals, Inc.
Table of Contents
1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 OCD Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Signs and Symptoms
2.5 Treatment
2.6 Referral Pathway
2.7 GlobalData Pipeline Report Guidance
3 OCD Therapeutics - Market Characterization
3.1 OCD Therapeutics Market Size (2005–2010) – Global
3.2 OCD Therapeutics Market Forecast (2010–2017) – Global
3.3 OCD Therapeutics Market Size (2005–2010) – The US
3.4 OCD Therapeutics Market Forecast (2010–2017) – The US
3.5 OCD Therapeutics Market Size (2005–2010) – France
3.6 OCD Therapeutics Market Forecast (2010–2017) – France
3.7 OCD Therapeutics Market Size (2005–2010) – Germany
3.8 OCD Therapeutics Market Forecast (2010–2017) – Germany
3.9 OCD Therapeutics Market Size (2005–2010) – Italy
3.10 OCD Therapeutics Market Forecast (2010–2017) – Italy
3.11 OCD Therapeutics Market Size (2005–2010) – Spain
3.12 OCD Therapeutics Market Forecast (2010–2017) – Spain
3.13 OCD Therapeutics Market Size (2005–2010) – The UK
3.14 OCD Therapeutics Market Forecast (2010–2017) – The UK
3.15 OCD Therapeutics Market Size (2005–2010) – Japan
3.16 OCD Therapeutics Market Forecast (2010–2017) – Japan
3.17 Drivers and Barriers for the OCD Therapeutics Market
3.17.1 Drivers for the OCD Therapeutics Market
3.17.2 Barriers for the OCD Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 OCD Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the OCD Therapeutics Market
4.3.1 Paxil (paroxetine)
4.3.2 Zoloft (sertraline hydrochloride)
4.3.3 Luvox CR (fluvoxamine)
4.3.4 Prozac (fluoxetine hydrochloride)
4.3.5 Anafranil (clomipramine hydrochloride)
4.4 Key Takeaway
5 OCD Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 OCD Therapeutics Pipeline – Pipeline by Phases of Development
5.3.1 OCD Therapeutics – Phase III Pipeline
5.3.2 OCD Therapeutics – Phase II Pipeline
5.3.3 OCD Market – Discovery and Pre-clinical Pipeline
5.3.4 Technology Trends Analytic Framework
5.4 OCD Therapeutics Market – Pipeline by Mechanism of Action
5.5 OCD Therapeutics – Promising Drugs Under Clinical Development
5.6 Molecule Profile for Promising Drugs Under Clinical Development
5.6.1 Gamunex-C
5.7 Key Takeaway
6 OCD Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in OCD Therapeutics Clinical Trials
7 Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 OCD Therapeutics - Implications for Future Market Competition
8 OCD Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Transcept Pharmaceuticals, Inc.
9 OCD Therapeutics - Licensing and Partnership Deals
10 OCD Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Disclaimer
10.7 Bibliography
List of Tables
1.1 List of Tables
Table 1: Common Obsessions in OCD
Table 2: OCD Therapeutics Market, Global, Revenue ($m), 2005–2010
Table 3: OCD Therapeutics Market, Global, Forecast ($m), 2010–2017
Table 4: OCD Therapeutics Market, The US, Revenue ($m), 2005–2010
Table 5: OCD Therapeutics Market, The US, Forecasts ($m), 2010–2017
Table 6: OCD Therapeutics Market, France, Revenue ($m), 2005–2010
Table 7: OCD Therapeutics Market, France, Forecasts ($m), 2010–2017
Table 8: OCD Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 9: OCD Therapeutics Market, Germany, Forecasts ($m), 2010–2017
Table 10: OCD Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 11: OCD Therapeutics Market, Italy, Forecasts ($m), 2010–2017
Table 12: OCD Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 13: OCD Therapeutics Market, Spain, Forecasts ($m), 2010–2017
Table 14: OCD Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 15: OCD Therapeutics Market, The UK, Forecasts ($m), 2010–2017
Table 16: OCD Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 17: OCD Therapeutics Market, Japan, Forecasts ($m), 2010–2017
Table 18: Outcome Classification (%) on CGI-Global Improvement Item for Completers in Study 1
Table 19: Outcome Classification (%) on CGI-Global Improvement Item for Completers in Study 1
Table 20: OCD Therapeutics, Phase III Pipeline, 2011
Table 21: OCD Therapeutics, Phase II Pipeline, 2011
Table 22: OCD Therapeutics, Discovery and Preclinical Pipeline, 2011
Table 23: OCD Therapeutics – Most Promising Drugs Under Clinical Development, 2011
Table 24: OCD Therapeutics, Clinical Trials by Country, 2011
Table 25: OCD Therapeutics – Clinical Trials by Phase, 2011
Table 26: OCD Therapeutics, Clinical Trials by Status (%), 2011
Table 27: OCD Therapeutics, Prominent Sponsors, 2011
Table 28: OCD Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 29: Transcept Pharmaceuticals Inc., Product Pipeline, 2011
Table 30: OCD Therapeutics, Global, Deals, 2010-2011
List of Figures
1.2 List of Figures
Figure 1: OCD Therapeutics Drug Dosage Pattern
Figure 2: Referral Pathway for Obsessive Compulsive Disorders
Figure 3: OCD Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 4: OCD Therapeutics Market, Global, Forecast ($m), 2010–2017
Figure 5: OCD Therapeutics Market, The US, Revenue ($m), 2005–2010
Figure 6: OCD Therapeutics Market, The US, Forecast ($m), 2010–2017
Figure 7: OCD Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 8: OCD Therapeutics Market, France, Forecast ($m), 2010–2017
Figure 9: OCD Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 10: OCD Therapeutics Market, Germany, Forecast ($m), 2010–2017
Figure 11: OCD Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 12: OCD Therapeutics Market, Italy, Forecast ($m), 2010–2017
Figure 13: OCD Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 14: OCD Therapeutics Market, Spain, Forecast ($m), 2010–2017
Figure 15: OCD Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 16: OCD Therapeutics Market, The UK, Forecast ($m), 2010–2017
Figure 17: OCD Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 18: OCD Therapeutics Market, Japan, Forecast ($m), 2010–2017
Figure 19: Opportunity and Unmet Need in the OCD Therapeutics Market, 2010
Figure 20: OCD Therapeutics, Strategic Competitor Assessment, 2010
Figure 21: OCD Therapeutics – Pipeline by Phase of Development, 2011
Figure 22: OCD Therapeutics, Technology Trends Analytics Framework, 2011
Figure 23: OCD Therapeutics, Technology Trends Analytics Framework, Description, 2011
Figure 24: OCD Therapeutics, Pipeline by Mechanism of Action (%), 2011
Figure 25: Gamunex-C Clinical Trial Details
Figure 26: OCD Therapeutics, Clinical Trials by Country, 2011
Figure 27: OCD Therapeutics, Clinical Trials by Phase (%), 2011
Figure 28: OCD Therapeutics, Clinical Trials by Status (%), 2011
Figure 29: OCD Therapeutics, Overall Sponsors (%), 2011
Figure 30: OCD Therapeutics, Prominent Sponsors (%), 2011
Figure 31: OCD Therapeutics, Top Companies Participating in Clinical Trials, 2011
Figure 32: OCD Therapeutics Market, Drivers and Restraints, 2011
Figure 33: Implications for Future Market Competition in the OCD Market, 2011
Figure 34: OCD Therapeutics Market, Pipeline by Company, 2011
Figure 35: GlobalData Market Forecasting Model
